MONDAY, OCTOBER 22
REGISTRATION
10:00 a.m.-8:00 p.m.
EDUCATIONAL SESSION 1: PREDICTIVE BIOMARKERS AND FUNCTIONAL IMAGING AS AIDS TO DRUG DEVELOPMENT
1:30 p.m.-3:30 p.m.
Chairperson: Julius Leyton, Imperial College London, London, England
PET Tracers as Biomarkers in Oncology Drug Development
Julius Leyton
Pharmacogenomic Applications in Oncology Drug Development
Nicholas C. Dracopoli, Bristol-Myers Squibb Company, Princeton, NJ, USA
Functional Imaging as Aids to Drug Development
Patricia M. Price, Christie Hospital NHS Trust, Manchester, England
EDUCATIONAL SESSION 2: MICRO AND INTERFERING RNAS IN DISEASE CAUSATION, TARGET VALIDATION, AND CANCER TREATMENT
3:30 p.m.-5:30 p.m.
Chairperson: Frank Slack, Yale University, New Haven, CT, USA
MicroRNAs in Cancer
Frank Slack
MicroRNAs in the Response to Cancer Therapy
Joanne B. Weidhaas, Yale University School of Medicine, New Haven, CT, USA
Toward a Non-Coding RNA Revolution in the Cancer Society
George A. Calin, UT M. D. Anderson Cancer Center, Houston, TX, USA
miRNAs as Oncogenes, Tumor Suppressors, and Therapeutic Intervention Points
David Brown, Asuragen, Inc., Austin, TX, USA
OPENING RECEPTION
6:00 p.m.-7:30 p.m.
TUESDAY, OCTOBER 23
OPENING REMARKS
8:00 a.m.-8:05 a.m.
KEYNOTE ADDRESSES
8:05 a.m.-10:05 a.m.
Molecular Profiling and Breast Cancer: Towards Better Risk Estimation, Prognostication, and Prediction
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway
Discovery of Disease Alleles and Drug Targets in Myeloid Leukemias
Dwight Gary Gilliland, Harvard Medical School, Boston, MA, USA
PLENARY SESSION 1: CANCER STEM CELLS
10:30 a.m.-12:30 p.m.
Session Chairperson: Peter B. Dirks, Hospital for Sick Children, Toronto, ON, Canada
Brain Tumor Stem Cells: Chemical Determinants of Self Renewal
Peter B. Dirks
Examining the Role of Stem Cell Biology in Lung Cancer
Carla Kim, Children's Hospital, Boston, MA, USA
Characterization and Targeting of Human Leukemia Stem Cells
Craig T. Jordan, University of Rochester School of Medicine, Rochester, NY, USA
Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma
Laurie Ailles, Stanford University School of Medicine, Palo Alto, CA, USA
POSTER SESSION A / EXHIBITS
12:30 p.m.-2:30 p.m.
PLENARY SESSION 2: TARGETING DNA REPAIR PATHWAYS
2:30 p.m.-4:30 p.m.
Chairperson: Alan Ashworth, Institute of Cancer Research, London, England
DNA Damage-Activated Kinases as Targets for Cancer Therapy
Roger J. Griffin, University of Newcastle upon Tyne, Newcastle upon Tyne, England
Targeting Fanconi Anemia / BRCA Pathway Defects in Cancer Therapeutics
Alan D. D'Andrea, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Right Silencing and Stratified Therapy in Glioblastoma
Monika E. Hegi, University Hospital, Lausanne, Switzerland
ERCC1 as Relevant Targets in the DNA Repair Pathway
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France
PROFFERED PAPER SESSION 1
4:30 p.m.-5:30 p.m.
POSTER SESSION A (CONTINUED) / EXHIBITS
5:30 p.m.-7:30 p.m.
WEDNESDAY, OCTOBER 24
PLENARY SESSION 3: EPIGENETIC TARGETS
8:00 a.m.-10:00 a.m.
Chairperson: Kristian Helin, University of Copenhagen, Copenhagen, Denmark
Histone Methyltransferases and Demethylases in Cell Proliferation and Cancer
Kristian Helin
Title to be announced
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, USA
The Cancer Epigenome
Peter A. Jones, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
Chromatin Alterations in Leukemias
Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy
PLENARY SESSION 4: GENOME-WIDE APPROACHES TO DIAGNOSIS, STRATIFICATION, AND TARGET IDENTIFICATION
10:30 a.m.-12:30 p.m.
Chairperson: Louis M. Staudt, National Cancer Institute, Bethesda, MD, USA
Cancer Genetic Markers of Susceptibility: Genome-wide Association Studies in Breast and Prostate Cancer
Stephen Chanock, National Cancer Institute, Bethesda, MD, USA
Predicting Effectiveness and Understanding Resistance to Targeted Inhibitors: Lessons from EGFR in Lung Cancer
Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA
Mechanisms of Resistance to NOTCH1 Inhibitors in T-ALL
Adolfo Ferrando, Columbia University Medical Center, New York, NY, USA
From Genomic Diversity to Tumor Dependency in Human Cancer
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA
POSTER SESSION B / EXHIBITS
12:30 p.m.-2:30 p.m.
CONCURRENT SESSIONS 1 - 4
2:30 p.m.-4:30 p.m.
- HIGH THROUGHPUT SCREENS FOR TARGET IDENTIFICATION
Chairperson: René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- Biomarkers of Resistance to Cancer Therapy Discovered through Functional Genetic Screens
René Bernards
- Functional Genomics of Chemosensitivity Exposes Deviant Cancer Cell Regulatory Systems
Michael A. White, University of Texas Southwestern Medical Center, Dallas, TX, USA
- Achilles Heel RNA Interference Screens for Molecular Targets in Cancer
Louis M. Staudt, National Cancer Institute, Bethesda, MD, USA
- Using Cellular Pharmacogenomics to Identify and Prioritize Genetic Determinants of Drug Response
Jeffrey M. Trent, Translational Genomics Research Institute, Phoenix, AZ, USA
- SMALL MOLECULE APPROACHES TO THE REGULATION OF APOPTOSIS
Chairperson: Louis J. Lombardo, Bristol-Myers Squibb Company, Princeton, NJ, USA
- Design of Small-molecule SMAC Mimetics as Apoptosis Inducers in Tumor Cells: Molecular Insights into Apoptosis Regulation
Shaomeng Wang, University of Michigan, Ann Arbor, MI, USA
- Drugging “Undruggable” Targets
Gregory L. Verdine, Harvard University, Cambridge, MA, USA
- Structure-based Design of IAP Antagonists
Wayne J. Fairbrother, Genentech, Inc., South San Francisco, CA, USA
- Apoptosis Based Therapies from a Medicinal Chemistry Perspective
Maurizio Pellecchia, The Burnham Institute, La Jolla, CA
- TUMOR MICROENVIRONMENT AND METASTASIS
Chairperson: Valerie M. Weaver, University of California, San Francisco, CA, USA
- Spatial-Mechanical Cues from the Microenvironment Modulate Malignant Transformation and Treatment Efficacy
Valerie M. Weaver
- Molecular Mechanisms Promoting Tumor Metastasis to Lymph Nodes and Beyond
Judith A. Varner, University of California San Diego Cancer Center, La Jolla, CA, USA
- Cancer Therapeutic Agents Act Directly on Targets in the Microenvironment
Michael B. Sporn, Dartmouth Medical School, Hanover, NH, USA
- Lymphatic Metastasis: How Tumor Cells Find the Best Escape Route
Melody Swartz, Ecole Polytechnique Federale de Lausanne School of Life Sciences, Lausanne, Switzerland
- EMERGING KINASE TARGETS
Chairperson: Judith S. Sebolt-Leopold, Ann Arbor, MI, USA
- Genetic Predictors of MAP Kinase Dependence
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- Targeting the IGF Receptor as Treatment for Cancer
V. M. Macaulay, Weatherall Institute of Molecular Medicine, Oxford, England
- Exploiting the Kinome to Target Cell Cycle Regulation
Michelle D. Garrett, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
- Cell Growth Control by mTORC1 and S6K Signaling
John Blenis, Harvard Medical School, Boston, MA
PROFFERED PAPER SESSION 2
4:30 p.m.-5:30 p.m.
POSTER SESSION B (CONTINUED) / EXHIBITS
5:30 p.m.-7:30 p.m.
THURSDAY, OCTOBER 25
PLENARY SESSION 5: TUMOR IMMUNOLOGY
8:00 a.m.-10:00 a.m.
Chairperson: James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Immune Checkpoint Blockade in Cancer Therapy
James P. Allison
Regulating Regulatory T Cells: A Novel Strategy to Augment Anti-tumor Immunity
Bernard A. Fox, Earle A. Chiles Research Institute, Portland, OR, USA
Failure at the Effector Phase: Immune Resistance in the Tumor Microenvironment
Thomas Frank Gajewski, University of Chicago, Chicago, IL, USA
Immunogenicity of Cytotoxic Drugs: Molecular Bases and Clinical Implementation
Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France
PLENARY SESSION 6: TOWARDS PERSONALIZED CANCER THERAPY (TALKS AND PANEL DISCUSSION)
10:30 a.m.-12:30 p.m.
Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC, USA
Molecular Diagnostics: A Need to Improve Cancer Care
Laura J. van't Veer, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Integrated Genomic Test to Aid Treatment Selection
Lajos Pusztai, UT M.D. Anderson Cancer Center, Houston, TX, USA
Optimizing Therapy through Pharmacogenomics
Kathleen D. Danenberg, Response Genetics, Inc., Los Angeles, CA, USA
HER2/neu- A Practical Example
Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Panel Discussion
POSTER SESSION C / EXHIBITS
12:30 p.m.-2:30 p.m.
CONCURRENT SESSIONS 5 - 8
2:30 p.m.-4:30 p.m.
- CANCER CELL METABOLISM
Chairperson: Craig B. Thompson, University of Pennsylvania, Philadelphia, PA, USA
- Therapeutic Targeting of Cancer Cell Metabolism
Craig B. Thompson
- Cancer Cell Metabolism in the Crosshairs: Targeting the mTOR Pathway for Cancer Therapy
Robert T. Abraham, Wyeth Pharmaceuticals, Pearl River, NY, USA
- Targeting Survivin in Cancer Therapy: Fulfilled Promises and Open Questions
Nadia Zaffaroni, Istituto Nazionale Tumori, Milan, Italy
- Role of the MZ Splice Isoform of Pyruvate Kinase in Aerobic Glycolysis and Tumorigenesis
Heather Christofk, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- RATIONAL DRUG COMBINATIONS
Chairperson: Roman Perez-Soler, Montefiore Medical Center, Bronx, NY, USA
- Synergistic Schedules with Combinations of EGFR Inhibitors and Cytotoxic Agents
Roman Perez-Soler
- Epigenetic Therapies: What's the Target?
Steven D. Gore, Johns Hopkins University, Baltimore, MD, USA
- Combinations with Angiogenesis Inhibitors
John V. Heymach, UT M. D. Anderson Cancer Center, Houston, TX, USA
- Multi-targeted Suppression of the RAS-AKT Signaling Network in NSCLC
Hayley M. McDaid, Albert Einstein College of Medicine, Bronx, NY, USA
- PROTEIN STABILITY AND TURNOVER
Chairperson: Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY. USA
- Hsp90-dependent Protein Folding as a Therapeutic Target in Cancer
Neal Rosen
- Novel Discovery of MLN4924, a Novel, First in Class nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer
Mark Rolfe, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA
- Regulation of hsp90 Chaperone Activity by Acetylation
Leonard M. Neckers, National Cancer Institute, Rockville, MD, USA
- Exploiting Molecular Chaperone Addiction in Cancer: New Drugs and Biomarkers
Paul Workman, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
- RE-ENGINEERING TUMOR SUPPRESSION
Chairperson: Karen H. Vousden, Beatson Institute for Cancer Research, Glasgow, Scotland
- The p53 Tumor Suppressor as a Therapeutic Target
Karen H. Vousden
- Overcoming the Loss of Mitochondrial Tumor Suppressors by Reactivating HIF Prolyl Hydroxylases
Eyal Gottlieb, Beatson Institute for Cancer Research, Glasgow, Scotland
- Targeting Bcl-2 Family Proteins to Treat Cancer
Steven W. Elmore, Abbott Laboratories, Abbott Park, IL, USA
- Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects
Alan Ashworth, Institute of Cancer Research, London, England
PROFFERED PAPER SESSION 3
4:30 p.m.-5:30 p.m.
POSTER SESSION C (CONTINUED) / EXHIBITS
5:30 p.m.-7:30 p.m.
FRIDAY, OCTOBER 26
PLENARY SESSION 7: THERAPEUTIC POTENTIAL OF DEVELOPMENTAL GENES
8:00 a.m.-10:00 a.m.
Chairperson: Jon C. Aster, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Targeting Notch in Cancer: Challenges and Opportunities
Jon C. Aster
Novel Molecular Targets in Breast Cancer Progression
Lewis A. Chodosh, University of Pennsylvania, Philadelphia, PA, USA
Notch 1 Inhibitors in Mouse T-ALL Models
Michelle A. Kelliher, University of Massachusetts Medical School, Worcester, MA, USA
Targeting Notch Signaling in Cancer
Christian W. Siebel, Genentech, Inc., South San Francisco, CA, USA
PLENARY SESSION 8: NEW CLINICAL TRIAL DESIGN (TALKS AND PANEL DISCUSSION)
10:30 a.m.-12:30 p.m.
Chairperson: James H. Doroshow, National Cancer Institute, Bethesda, MD, USA
Potential Utilities of the Study of Circulating Tumor Cells in the Design of Clinical Trials of Molecularly Targeted Drugs
Johann S. de Bono, Royal Marsden Hospital, Institute for Cancer Research, Sutton, Surrey, England
New Concepts in Phase II Design
Mark J. Ratain, University of Chicago, Chicago, IL, USA
Clinical Trial Designs for Early Drug Development
James A. Zwiebel, National Cancer Institute, Rockville, MD, USA
Title to be announced
Francesco Pignatti, The European Medicines Agency, London, England
CLOSING CEREMONY
12:30 p.m-12:45 p.m.
DEPARTURE